RemedyRepack Inc. is recalling 66 bottles (totaling 5,940 tablets) of Valsartan in 80 mg, 160 mg, and 320 mg strengths. This recall was initiated because the active pharmaceutical ingredient (API) used to manufacture the tablets was found to contain a nitrosamine impurity, which is classified as a possible human carcinogen. These prescription medications are used to treat high blood pressure and heart failure, and were distributed in white plastic bottles within cardboard trays to customers in Florida and Virginia.
The tablets contain an impurity that is linked to an increased risk of cancer. While there have been no reported injuries or adverse events at this time, the presence of this impurity deviates from safe manufacturing standards.
Contact healthcare provider and return product to pharmacy.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.